Jiao Xue-Feng, Zhang Zhengyang, Gong Lixiong, Lan Shan, Zhang Songzhen, Wang Jiang, Chen Xiubi, Wei Qiang, Li Hailong, Zeng Linan, Han Lu, Zhang Lingli
Department of Pharmacy/Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University, Children's Medicine Key Laboratory of Sichuan Province, Renmin Nan Road 20, Chengdu, 610041, China.
NMPA Key Laboratory for Technical Research On Drug Products In Vitro and In Vivo Correlation, Chengdu, China.
Eur J Clin Pharmacol. 2025 Feb;81(2):309-319. doi: 10.1007/s00228-024-03790-7. Epub 2024 Dec 17.
To systematically review the characteristics of the available pharmacovigilance signal detection studies in pregnancy, and comprehensively assess the reliability, transparency, reporting, and interpretation of these studies.
We searched five databases from inception to February 2024 to identify the available pharmacovigilance signal detection studies in pregnancy. We extracted three aspects of information (basic information, data processing modes, signal detection analyses) to assess the reliability, transparency, and reporting of each study. Moreover, we adopted the criteria of Mouffak et al.'s study to assess the misinterpretation of signal detection results in these studies.
A total of 33 pharmacovigilance signal detection studies in pregnancy were identified. Among them, there were great methodological heterogeneities in the data processing modes (restriction to the population, comparator, standardization of drug names and adverse event names, the assigned roles of drugs, counting unit, etc.) and signal detection analyses (signal detection method, sensitivity analysis, subgroup analysis, adjustment for confounding factors, etc.). Moreover, 13 (39%) studies had at least one type of inappropriate interpretation and/or extrapolation of signal detection results.
Our results reveals that the quantity of pharmacovigilance signal detection studies in pregnancy is relatively limited. Furthermore, the reliability, transparency, reporting, and interpretation of the existing studies are less optimistic. The main issues existing in the available pharmacovigilance signal detection studies in pregnancy consist of two aspects: (1) great methodological heterogeneities exist in the data processing modes and signal detection analyses among different studies and (2) inappropriate interpretation and extrapolation of signal detection results are frequent.
系统回顾妊娠期可用的药物警戒信号检测研究的特征,并全面评估这些研究的可靠性、透明度、报告情况及解读。
我们检索了从建库至2024年2月的五个数据库,以识别妊娠期可用的药物警戒信号检测研究。我们提取了三个方面的信息(基本信息、数据处理模式、信号检测分析)来评估每项研究的可靠性、透明度和报告情况。此外,我们采用穆法克等人研究的标准来评估这些研究中信号检测结果的错误解读。
共识别出33项妊娠期药物警戒信号检测研究。其中,在数据处理模式(对人群的限制、对照、药物名称和不良事件名称的标准化、药物的指定作用、计数单位等)和信号检测分析(信号检测方法、敏感性分析、亚组分析、混杂因素调整等)方面存在很大的方法学异质性。此外,13项(39%)研究至少有一种对信号检测结果的不恰当解读和/或外推。
我们的结果表明,妊娠期药物警戒信号检测研究的数量相对有限。此外,现有研究的可靠性、透明度、报告情况及解读不容乐观。妊娠期可用的药物警戒信号检测研究中存在的主要问题包括两个方面:(1)不同研究之间在数据处理模式和信号检测分析方面存在很大的方法学异质性;(2)信号检测结果的不恰当解读和外推很常见。